807344-35-0

Basic information

• Product Name: C₅₁H₆₁N₁₁O₁₁
• Synonyms: C₅₁H₆₁N₁₁O₁₁
• CAS NO: 807344-35-0
• Molecular Weight: 1004.11
• Mol File: 807344-35-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₅₁H₆₁N₁₁O₁₁(CAS DataBase Reference)
• NIST Chemistry Reference: C₅₁H₆₁N₁₁O₁₁(807344-35-0)
• EPA Substance Registry System: C₅₁H₆₁N₁₁O₁₁(807344-35-0)

Safety Data

• Hazardous Substances Data: 807344-35-0(Hazardous Substances Data)

Upstream product

• 714978-25-3 C₁₇H₂₅N₃O₄S 
• 714978-33-3 [2-(3-{[(methylcarbamoylmethyl-carbamoyl)-methyl]-carbamoyl}-propionylamino)-acetylamino]-acetic acid 
• 714978-29-7 C₃₈H₄₂N₆O₅ 
• 807344-32-7 [2-(3-{[(methylcarbamoylmethyl-carbamoyl)-methyl]-carbamoyl}-propionylamino)-acetylamino]-acetic acid benzyl ester 
• 67819-42-5 Z-(Gly)2-NH-CH₃ 
• 92235-99-9 glycylglycine-N-methylamide 
• 71145-35-2 succinyl-Gly-Gly-OBzl 
• 501-53-1 benzyl chloroformate 

Relevant articles and documents

A bivalent ligand (KDN-21) reveals spinal δ and κ opioid receptors are organized as heterodimers that give rise to δ1 and δ2 phenotypes. Selective targeting of δ-κ heterodimers

In view of recent pharmacological studies suggesting the existence of δ-κ opioid receptor heterodimers/oligomers in the spinal cord, we have synthesized and evaluated (intrathecally in mice) a series of bivalent ligands (KDN series) containing κ and δ antagonist pharmacophores. Pharmacological and binding data have provided evidence for the bridging of spinal δ-κ receptor heterodimers by KDN-21 and for their identification as δ1 and κ2. The selectivity profile of KDN-21 and the apparent absence of coupled δ 1-κ2 phenotypes in the brain suggest a new approach for targeting receptors.